Johan Raud
Hoofd Techniek/Wetenschap/O&O bij VICORE PHARMA HOLDING AB
Oorsprong van het eerstegraads netwerk van Johan Raud
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 25 | |
KI Management AB
 KI Management AB Investment ManagersFinance KI Management AB (KIM) is a venture capital investment firm located in Stockholm, on the campus of the Karolinska Institute. They are the investment advisor and manager of the Karolinska Investment Fund KB (KIF). The fund was established in 1999 by the Karolinska Institute and Alecta, a Nordic pension plan. KIM has a partnership agreement with Karolinska Innovations AB, a technology transfer entity of the Karolinska Institute. The Karolinska Institute, founded in 1810, has a medical focus and is responsible for selecting the winner of the Nobel Prize in Physiology or Medicine.
1
| Extinct | Investment Managers | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Johan Raud via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| TAURUS ENERGY AB | Oil & Gas Production | Director/Board Member Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member | |
Top Institute Pharma
 Top Institute Pharma BiotechnologyHealth Technology Part of Center for Translational Molecular Medicine, Top Institute Pharma provides pharmaceutical research services. The company is based in Leiden, Netherlands. Top Institute Pharma was acquired by Center for Translational Molecular Medicine on June 09, 2015. | Biotechnology | Director/Board Member | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
| GLENMARK PHARMACEUTICALS LIMITED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| Karolinska Institutet | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
A+ Science Holding AB
 A+ Science Holding AB MiscellaneousMiscellaneous A+ Science Holding AB operates as an investment company, which operates in the field of medical and biotechnology sector. It invests in the life science sector and especially in human medicine. The company was founded in 1997 and is headquartered in Göteborg, Sweden. | Miscellaneous | Director/Board Member Chief Investment Officer Chief Executive Officer | |
| Stockholm School of Economics | College/University | Masters Business Admin Undergraduate Degree | |
| University of Uppsala | College/University | Undergraduate Degree Corporate Officer/Principal Corporate Officer/Principal Graduate Degree Graduate Degree | |
Vicore Pharma AB
 Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer Chairman Corporate Officer/Principal | |
| University of Lund | College/University | Undergraduate Degree Graduate Degree Doctorate Degree Undergraduate Degree | |
| University of Utrecht | College/University | Doctorate Degree | |
| University of Gothenburg | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
bioMérieux, Inc.
 bioMérieux, Inc. Medical SpecialtiesHealth Technology bioMérieux, Inc. develops in-vitro diagnostics solutions. It offers microbiological testing solutions for medical and industrial applications. The company was founded on December 31, 1986 and is headquartered in Durham, NC. | Medical Specialties | Corporate Officer/Principal | |
GU Ventures AB
 GU Ventures AB Investment ManagersFinance GU Ventures AB (GU Ventures) is a venture capital subsidiary of University of Gothenburg founded in 1995. The firm is headquartered in Gothenburg, Sweden. | Investment Managers | Private Equity Investor | |
| BONESUPPORT HOLDING AB | Medical Specialties | Corporate Officer/Principal | |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Pharmaceuticals: Major | Sales & Marketing | |
| Organon International BV | President | ||
| HANSA BIOPHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
| I-TECH AB | Chemicals: Major Diversified | Chief Executive Officer Chairman | |
| ORTOMA AB | Hospital/Nursing Management | President | |
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Major | Chairman | |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Chairman | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member | |
MetaboGen AB
 MetaboGen AB Internet Software/ServicesTechnology Services MetaboGen AB operates a metagenome and metabolic disease platform. It provides commercial access to metagenome research and development. The firm offers create next generation probiotics and pharmaceutical products, based on the microbiome. The company was founded in 2011 and is headquartered in Göteborg, Sweden. | Internet Software/Services | Chief Executive Officer | |
| Top Sector Life Sciences & Health | Director/Board Member | ||
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman | |
| WILSON THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Itin Holding AB | Director/Board Member Chairman | ||
| PHARVARIS N.V. | Pharmaceuticals: Major | Founder Director/Board Member | |
| Nefarma | Director/Board Member | ||
Microbiotica Ltd.
 Microbiotica Ltd. BiotechnologyHealth Technology Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chairman | |
Skipjack AB
 Skipjack AB Real Estate DevelopmentFinance Skipjack AB Manages real properties. The company is headquartered in Stockholm, Sweden. | Real Estate Development | Director/Board Member | |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member | |
Healthcap Annex Fund I-Ii Bis Gp AB
 Healthcap Annex Fund I-Ii Bis Gp AB Financial ConglomeratesFinance Healthcap Annex Fund I-Ii Bis Gp AB operates as an investment holding Swedish company. The private company is based in Stockholm, Sweden. | Financial Conglomerates | Director/Board Member | |
INIM Pharma AB
 INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Chairman Director/Board Member Director/Board Member | |
| EllAug AB | Director/Board Member | ||
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Founder | |
Synox Therapeutics Ltd.
 Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member | |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Miscellaneous Commercial Services | Director/Board Member | |
| Mips Helmet AB | Director/Board Member | ||
Disruptive Pharma AB
 Disruptive Pharma AB Pharmaceuticals: MajorHealth Technology Disruptive Pharma AB is a pharmaceutical company based in Uppsala, Sweden, with a passion for innovation in drug products. The Swedish company has perfected the groundbreaking mesoporous magnesium carbonate (mmc) drug delivery technology, which makes it easier to develop amorphous drug candidates. By combining the mmc formulation technology with drug compounds, they can enhance existing products or assist in formulating new therapies. Disruptive Pharma seeks commercial partnership or licensing to industry partners within the drug improvement business area. The company was founded in 2018 by Maria Strömme, and the CEO is Peter Åsberg. | Pharmaceuticals: Major | Director/Board Member | |
| Aurelia Invest AB | Director/Board Member |
Statistieken
Internationaal
| Zweden | 30 |
| Nederland | 9 |
| Zwitserland | 6 |
| Verenigde Staten | 4 |
| Oostenrijk | 2 |
Sectoraal
| Health Technology | 25 |
| Consumer Services | 7 |
| Finance | 6 |
| Commercial Services | 4 |
| Energy Minerals | 2 |
Operationeel
| Director/Board Member | 109 |
| Corporate Officer/Principal | 42 |
| Chairman | 31 |
| Chief Executive Officer | 25 |
| Independent Dir/Board Member | 23 |
Sterkste connecties
- Beurs
- Insiders
- Johan Raud
- Bedrijfsconnecties